



## Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

November 9, 2016

BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 9, 2016-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Amar Sawhney, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:

- **Stifel 2016 Healthcare Conference**

Tuesday, November 15, 2016 at 10:15 a.m. Eastern Time  
Lotte New York Palace Hotel, New York, NY

- **Piper Jaffray 28<sup>th</sup> Annual Healthcare Conference**

Wednesday, November 30, 2016 at 3:30 p.m. Eastern Time  
Lotte New York Palace Hotel, New York, NY

Live audio webcasts of the presentations can be accessed through the Calendar of Events section of the Company's website at [investors.ocutx.com](http://investors.ocutx.com). Replays of the webcasts will be available on the Company's website for two weeks following each presentation.

### About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix has submitted an NDA for post-surgical pain for its lead product candidate, DEXTENZA™ (dexamethasone insert), which is in Phase 3 clinical development for post-surgical ocular inflammation and pain and allergic conjunctivitis. OTX-TP (travoprost insert) is in Phase 3 clinical development for glaucoma and ocular hypertension. Ocular Therapeutix is also evaluating injectable drug delivery depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery. For additional information about the Company, please visit [www.ocutx.com](http://www.ocutx.com).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20161109005107/en/>

Source: Ocular Therapeutix, Inc.

### Investors

Ocular Therapeutix, Inc.

Brad Smith

Chief Financial Officer

[bsmith@ocutx.com](mailto:bsmith@ocutx.com)

or

Burns McClellan on behalf of Ocular Therapeutix

Steve Klass, 212-213-0006

[sklass@burnsmc.com](mailto:sklass@burnsmc.com)

or

### Media

Ocular Therapeutix, Inc.

Scott Corning

Vice President of Sales and Marketing

[scorning@ocutx.com](mailto:scorning@ocutx.com)